Ocugen rises on vaccine candidate's selection for NIAID clinical trial
10/10/2023 12:15
** Shares of therapy developer Ocugen OCGN.O rise 7.8% to
44 cents premarket
** Co says the National Institute of Allergy and Infectious
Diseases (NIAID) is conducting a trial with co's COVID-19
vaccine candidate
** The vaccine, OCU500, will be tested to compare its
administration via two different mucosal routes, inhalation into
the lungs and as a nasal spray
** The NIAID's study will evaluate several early stage
vaccine candidates in order to understand whether an inhaled
COVID-19 vaccine provides greater immune response compared to a
nasal spray vaccine
** Up to last close, shares down 68.6% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))